Cargando…
Immune-based therapies in the management of multiple myeloma
Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved progno...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443188/ https://www.ncbi.nlm.nih.gov/pubmed/32829378 http://dx.doi.org/10.1038/s41408-020-00350-x |
_version_ | 1783573585316544512 |
---|---|
author | Zanwar, Saurabh Nandakumar, Bharat Kumar, Shaji |
author_facet | Zanwar, Saurabh Nandakumar, Bharat Kumar, Shaji |
author_sort | Zanwar, Saurabh |
collection | PubMed |
description | Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved prognosis. This has in turn resulted in an increasing number of patients in need of therapy for relapsed/refractory disease. Immune-based therapies, including monoclonal antibodies, immune checkpoint inhibitors, and most promisingly, adoptive cellular therapies represent important therapeutic strategies in these patients due to their non-cross resistant mechanisms of actions with the usual frontline therapies comprising of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). The anti-CD38 antibodies daratumumab and more recently isatuximab, with their excellent efficacy and safety profile along with its synergy in combination with IMiDs and PIs, are being increasingly incorporated in the frontline setting. Chimeric antigen receptor–T cell (CART) therapies and bi-specific T-cell engager (BiTE) represent exciting new options that have demonstrated efficacy in heavily pretreated and refractory MM. In this review, we discuss the rationale for use of immune-based therapies in MM and summarize the currently available literature for common antibodies and CAR-T therapies that are utilized in MM. |
format | Online Article Text |
id | pubmed-7443188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-74431882020-09-02 Immune-based therapies in the management of multiple myeloma Zanwar, Saurabh Nandakumar, Bharat Kumar, Shaji Blood Cancer J Review Article Multiple myeloma (MM) is a clonal plasma cell malignancy affecting a predominantly elderly population. The continued development of newer therapies with novel mechanisms of action has reshaped the treatment paradigm of this disorder in the last two decades, leading to a significantly improved prognosis. This has in turn resulted in an increasing number of patients in need of therapy for relapsed/refractory disease. Immune-based therapies, including monoclonal antibodies, immune checkpoint inhibitors, and most promisingly, adoptive cellular therapies represent important therapeutic strategies in these patients due to their non-cross resistant mechanisms of actions with the usual frontline therapies comprising of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). The anti-CD38 antibodies daratumumab and more recently isatuximab, with their excellent efficacy and safety profile along with its synergy in combination with IMiDs and PIs, are being increasingly incorporated in the frontline setting. Chimeric antigen receptor–T cell (CART) therapies and bi-specific T-cell engager (BiTE) represent exciting new options that have demonstrated efficacy in heavily pretreated and refractory MM. In this review, we discuss the rationale for use of immune-based therapies in MM and summarize the currently available literature for common antibodies and CAR-T therapies that are utilized in MM. Nature Publishing Group UK 2020-08-22 /pmc/articles/PMC7443188/ /pubmed/32829378 http://dx.doi.org/10.1038/s41408-020-00350-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Zanwar, Saurabh Nandakumar, Bharat Kumar, Shaji Immune-based therapies in the management of multiple myeloma |
title | Immune-based therapies in the management of multiple myeloma |
title_full | Immune-based therapies in the management of multiple myeloma |
title_fullStr | Immune-based therapies in the management of multiple myeloma |
title_full_unstemmed | Immune-based therapies in the management of multiple myeloma |
title_short | Immune-based therapies in the management of multiple myeloma |
title_sort | immune-based therapies in the management of multiple myeloma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443188/ https://www.ncbi.nlm.nih.gov/pubmed/32829378 http://dx.doi.org/10.1038/s41408-020-00350-x |
work_keys_str_mv | AT zanwarsaurabh immunebasedtherapiesinthemanagementofmultiplemyeloma AT nandakumarbharat immunebasedtherapiesinthemanagementofmultiplemyeloma AT kumarshaji immunebasedtherapiesinthemanagementofmultiplemyeloma |